Cargando…
Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
Medulloblastoma (MB) is the most common solid tumour in children and, despite current treatment with a rather aggressive combination therapy, accounts for 10% of all deaths associated with paediatric cancer. Breaking the tumour cells’ intrinsic resistance to therapy-induced cell death should lead to...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779796/ https://www.ncbi.nlm.nih.gov/pubmed/35056150 http://dx.doi.org/10.3390/ph15010091 |
_version_ | 1784637665297039360 |
---|---|
author | Westhoff, Mike-Andrew Schuler-Ortoli, Marie Zerrinius, Daniela Hadzalic, Amina Schuster, Andrea Strobel, Hannah Scheuerle, Angelika Wong, Tiana Wirtz, Christian Rainer Debatin, Klaus-Michael Peraud, Aurelia |
author_facet | Westhoff, Mike-Andrew Schuler-Ortoli, Marie Zerrinius, Daniela Hadzalic, Amina Schuster, Andrea Strobel, Hannah Scheuerle, Angelika Wong, Tiana Wirtz, Christian Rainer Debatin, Klaus-Michael Peraud, Aurelia |
author_sort | Westhoff, Mike-Andrew |
collection | PubMed |
description | Medulloblastoma (MB) is the most common solid tumour in children and, despite current treatment with a rather aggressive combination therapy, accounts for 10% of all deaths associated with paediatric cancer. Breaking the tumour cells’ intrinsic resistance to therapy-induced cell death should lead to less aggressive and more effective treatment options. In other tumour entities, this has been achieved by modulating the balance between the various pro- and anti-apoptotic members of the Bcl-2 family with small molecule inhibitors. To evaluate the therapeutic benefits of ABT-199 (Venetoclax), a Bcl-2 inhibitor, and ABT-263 (Navitoclax), a dual Bcl-XL/Bcl-2 inhibitor, increasingly more relevant model systems were investigated. Starting from established MB cell lines, progressing to primary patient-derived material and finally an experimental tumour system imbedded in an organic environment were chosen. Assessment of the metabolic activity (a surrogate readout for population viability), the induction of DNA fragmentation (apoptosis) and changes in cell number (the combined effect of alterations in proliferation and cell death induction) revealed that ABT-263, but not ABT-199, is a promising candidate for combination therapy, synergizing with cell death-inducing stimuli. Interestingly, in the experimental tumour setting, the sensitizing effect of ABT-263 seems to be predominantly mediated via an anti-proliferative and not a pro-apoptotic effect, opening a future line of investigation. Our data show that modulation of specific members of the Bcl-2 family might be a promising therapeutic addition for the treatment of MB. |
format | Online Article Text |
id | pubmed-8779796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87797962022-01-22 Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy Westhoff, Mike-Andrew Schuler-Ortoli, Marie Zerrinius, Daniela Hadzalic, Amina Schuster, Andrea Strobel, Hannah Scheuerle, Angelika Wong, Tiana Wirtz, Christian Rainer Debatin, Klaus-Michael Peraud, Aurelia Pharmaceuticals (Basel) Article Medulloblastoma (MB) is the most common solid tumour in children and, despite current treatment with a rather aggressive combination therapy, accounts for 10% of all deaths associated with paediatric cancer. Breaking the tumour cells’ intrinsic resistance to therapy-induced cell death should lead to less aggressive and more effective treatment options. In other tumour entities, this has been achieved by modulating the balance between the various pro- and anti-apoptotic members of the Bcl-2 family with small molecule inhibitors. To evaluate the therapeutic benefits of ABT-199 (Venetoclax), a Bcl-2 inhibitor, and ABT-263 (Navitoclax), a dual Bcl-XL/Bcl-2 inhibitor, increasingly more relevant model systems were investigated. Starting from established MB cell lines, progressing to primary patient-derived material and finally an experimental tumour system imbedded in an organic environment were chosen. Assessment of the metabolic activity (a surrogate readout for population viability), the induction of DNA fragmentation (apoptosis) and changes in cell number (the combined effect of alterations in proliferation and cell death induction) revealed that ABT-263, but not ABT-199, is a promising candidate for combination therapy, synergizing with cell death-inducing stimuli. Interestingly, in the experimental tumour setting, the sensitizing effect of ABT-263 seems to be predominantly mediated via an anti-proliferative and not a pro-apoptotic effect, opening a future line of investigation. Our data show that modulation of specific members of the Bcl-2 family might be a promising therapeutic addition for the treatment of MB. MDPI 2022-01-14 /pmc/articles/PMC8779796/ /pubmed/35056150 http://dx.doi.org/10.3390/ph15010091 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Westhoff, Mike-Andrew Schuler-Ortoli, Marie Zerrinius, Daniela Hadzalic, Amina Schuster, Andrea Strobel, Hannah Scheuerle, Angelika Wong, Tiana Wirtz, Christian Rainer Debatin, Klaus-Michael Peraud, Aurelia Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy |
title | Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy |
title_full | Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy |
title_fullStr | Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy |
title_full_unstemmed | Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy |
title_short | Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy |
title_sort | bcl-xl but not bcl-2 is a potential target in medulloblastoma therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779796/ https://www.ncbi.nlm.nih.gov/pubmed/35056150 http://dx.doi.org/10.3390/ph15010091 |
work_keys_str_mv | AT westhoffmikeandrew bclxlbutnotbcl2isapotentialtargetinmedulloblastomatherapy AT schulerortolimarie bclxlbutnotbcl2isapotentialtargetinmedulloblastomatherapy AT zerriniusdaniela bclxlbutnotbcl2isapotentialtargetinmedulloblastomatherapy AT hadzalicamina bclxlbutnotbcl2isapotentialtargetinmedulloblastomatherapy AT schusterandrea bclxlbutnotbcl2isapotentialtargetinmedulloblastomatherapy AT strobelhannah bclxlbutnotbcl2isapotentialtargetinmedulloblastomatherapy AT scheuerleangelika bclxlbutnotbcl2isapotentialtargetinmedulloblastomatherapy AT wongtiana bclxlbutnotbcl2isapotentialtargetinmedulloblastomatherapy AT wirtzchristianrainer bclxlbutnotbcl2isapotentialtargetinmedulloblastomatherapy AT debatinklausmichael bclxlbutnotbcl2isapotentialtargetinmedulloblastomatherapy AT peraudaurelia bclxlbutnotbcl2isapotentialtargetinmedulloblastomatherapy |